F ocal segmental glomerulosclerosis (FSGS) is a glomerular disease with a characteristic pathologic presentation that includes segmental scarring involving some but not all glomeruli. On immunofl uorescence, deposits of immunoglobulin (Ig) M and C3 may be found in the areas of segmental scarring. Electron microscopy typically demonstrates diff use epithelial cell foot process eff acement and focal areas of retraction of glomerular basement membrane with collapse of the involved tuft (1) . Due to the focal nature of the process, it is sometimes challenging to recognize this lesion in the biopsy specimen. Accordingly, special attention needs to be directed at the corticomedullary regions of the kidney where FSGS is more likely to be found. Otherwise, an errant diagnosis of minimal change disease could be made. Once underlying causes of this particular glomerular presentation are ruled out (such as obesity, sleep apnea, heroin abuse, refl ux nephropathy, and HIV), one is left with a diagnosis of primary or idiopathic FSGS. It is important to identify patients who present with nephroticrange proteinuria and have FSGS because early treatment of these patients may alter the course of the disease and prevent relentless progression to terminal renal failure (2) .
Th e collapsing form of FSGS, which occurs more commonly in African American patients than in Caucasians, carries a particularly poor prognosis with respect to renal survival (3) . Th is variant is morphologically similar to the glomerular lesion often associated with HIV infection. However, the term idiopathic collapsing glomerulopathy is reserved for patients who are HIV negative.
Collapsing glomerulopathy has been associated with non-HIV-related pathologies. Th ese include associations with medications like pamidronate and interferon-alfa and with viral infections like parvovirus B19, cytomegalovirus, and hepatitis C (4, 5) . Rarely, multiple myeloma has been associated with this lesion (6, 7) . A case of collapsing FSGS in a patient with parvovirus B19 infection is presented with review of the known literature.
CASE PRESENTATION
A 56-year-old African American man with a history of hypertension, hyperlipidemia, and chronic kidney disease, with a baseline serum creatinine of 1.9 mg/dL 4 months earlier, presented to the hospital with worsening fatigue and malaise.
Renal laboratory results had deteriorated, with a creatinine of 17 mg/dL and blood urea nitrogen of 94 mg/dL. He denied any recent use of nonsteroidal antiinfl ammatory drugs or herbal supplements and reported compliance with his medications, which included metoprolol 50 mg twice daily and verapamil (dose unknown). Physical examination was remarkable only for a blood pressure of 170/88 mm Hg and bilateral lower extremity edema. Urinanalysis revealed 3+ proteinuria, 1+ blood, and hyaline casts. Th e spot urine protein/creatinine ratio was 5.2 (normal, <0.2). Renal ultrasound revealed normal-sized kidneys with increased echogenicity. Tests for HIV by enzyme-linked immunosorbent assay and polymerase chain reaction were negative, as were tests for hepatitis B surface antigen and hepatitis C antibody and urine drug screens. Serum protein electrophoresis, urine protein electrophoresis, and urine immunofi xation revealed no monoclonal protein. Tests for parvovirus antibodies were positive, with titers of IgM 5.2 and IgG 4.5, indicative of active infection.
A renal biopsy revealed collapsing FSGS glomerulopathy with patchy tubular dilatation (Figure 1) . Th e patient's clinical course was characterized by nonoliguric renal failure and diffi cult-to-control hypertension. However, his renal function gradually improved with no specifi c therapy, with his serum creatinine falling to 4 mg/dL. Subsequent parvovirus IgM and IgT titers fell, indicating a resolution of his viral infection.
DISCUSSION
It is postulated that in collapsing glomerulopathy, unlike other podocytopathies, the podocyte dediff erentiates, and this results in a dysregulated phenotype (8) . Diseased podocytes exhibit a loss of diff erentiation and gain of proliferation. Podocytes have been described to "transdiff erentiate" towards a macrophage-like cell (9-13) (Figure 2) .
Patients with FSGS usually present with nephrotic-range proteinuria, hypertension, and decreased renal function. Th e collapsing variant of FSGS was fi rst recognized and described by Schwartz and Lewis (14) and was later confi rmed by Weiss et al (15) , Detwiler et al (16) , and Valeri et al (17) . Th ese patients are likely to have higher levels of proteinuria, are more commonly African American, and have a poor prognosis with more rapid progression to terminal renal failure.
Parvovirus B19 infection is a common disease, with 50% to 80% of adults having parvoviral-specifi c IgG. Th e infection is usually minimally symptomatic, but aplastic anemia can occur in patients with sickle cell disease and other chronic hemolytic disorders. Parvovirus B19 can evolve into a chronic infection in patients who are immunosuppressed. Clinical symptoms of active disease include skin rash and arthralgias.
FSGS has been described as a clinical consequence of parvovirus B19 infection (18) (19) (20) . Moudgil et al presented a series of 23 patients with collapsing glomerulopathy, and 18% of these cases revealed parvovirus B19 DNA in the renal specimens. In another series, 10 more cases of collapsing FSGS were reported by Tanawattanacharoen et al, where 90% of the cases had DNA evidence of parvovirus B19 in renal tissue (21) . It has been speculated that some patients have a predisposition that makes them susceptible to defects in their ability to generate a cellular and humoral immune response to clear this virus. Th e persistence of viremia increases the infectivity and has a possible impact on a variety of clinical disease presentations.
Th e collapsing variety of FSGS is rare. African Americans are hyperproducers of transforming growth factor B, a cytokine associated with fi brosis, which could contribute to excessive proliferative and sclerosing in response to a viral insult. In certain individuals, this may initiate a cascade of events in the kidney, which results in collapsing glomerulopathy (16, 18, 22, 23) . However, other individuals may have resistance to this viral infection due to lack of the viral receptor (in the erythrocytes and/or kidney tissue), which protects their renal epithelial cells from parvovirus infection. In our patient, there was a temporal relationship between active parvovirus B19 infection and the development of collapsing FSGS, with clinical improvement as the viral infection resolved.
No evidence-based therapy exists for collapsing FSGS. Current therapies are based on empiric experience and have been extrapolated from treatments used for FSGS. Treatments utilized include steroids, cyclophosphamide, and cyclosporine (9) . Th e usual recommended course of steroid therapy is 6 months of daily or alternate daily prednisone. Unfortunately, despite aggressive therapy, remission is uncommon. Various studies have reported full remission rates of 9.6% and partial remission rates of 15.2%. Furthermore, Crenshaw et al, in their retrospective series, did not fi nd a benefi cial eff ect of steroids in African Americans (3, 24) . For patients who are intolerant of prednisone, various immunosuppressives have been tried, again with variable success. A recent report presented a patient with cyclosporine-resistant collapsing FSGS who was successfully treated with rituximab and achieved a complete remission. Th erefore, this agent may emerge as yet another therapeutic option for patients with refractory collapsing FSGS (25) .
Treatment of hypertension is an important aspect of treatment for all patients with renal disease, regardless of etiology, and angiotensin-converting enzyme inhibitors (ACEIs) are considered fi rst-line drugs for this purpose. ACEIs control systemic hypertension and simultaneously reduce intraglomerular pressure and hence decrease proteinuria (3). Prasher et al assessed the effi cacy of enalapril in controlling proteinuria in steroid-resistant idiopathic nephrotic syndrome and found that enalapril exerted a long-lasting eff ect (26) . Also, a randomized controlled trial of losartan therapy in 23 normotensive patients with primary FSGS who were refractory to immunosuppressive therapy showed a reduction in proteinuria compared with the control group after 1 year of treatment (27) .
In summary, a rare subtype of FSGS called collapsing FSGS is reported. Th is glomerulopathy, often associated with active HIV infection, has a very aggressive course leading to terminal renal failure. In this case a coexistent acute parvovirus B19 infection was identifi ed. Th e patient's clinical presentation and renal biopsy fi ndings are indistinguishable from those features in patients with HIV nephropathy. Th is fi nding raises the possibility that parvovirus B19 may be the precipitating or causative etiologic agent for this form of FSGS. Th is possibility is further supported by the patient's marked clinical improvement as the parvovirus B19 infection resolved.
